VMPL Mumbai Maharashtra [India] October 3 Sahajanand Medical Technologies SMT is excited to announce the successful ...

[86] Results from these studies will provide pivotal data to address the use of dual antiplatelet therapy in the secondary prevention of ischemic vascular events. The Warfarin Antiplatelet Therapy ...

Analysis Comparing Oral Anticoagulant Monotherapy Versus Dual Antithrombotic Therapy in Patients With Atrial Fibrillation and ...

The following is a summary of “Bleeding complications, coagulation disorders, and their management in acute myocardial ...

Dual antiplatelet therapy with aspirin and clopidogrel is effective in limiting adverse coronary thromboischemic events in most patients undergoing coronary stenting. However, platelet reactivity ...

Sahajanand Medical Technologies successfully completed enrollment of 1,550 patients for the Multivessel TALENT trial, ...

After coronary stent implantation, prolonged dual antiplatelet therapy (DAPT) increases bleeding risk, requiring personalization of DAPT duration. The aim of this study was to develop and validate a ...

The risk of recurrent thrombotic events is highest within the first 3 months of the index event, and a short course of dual antiplatelet therapy (DAPT) reduces the risk of recurrent stroke. 1 Because ...

This unique dual formulation provides the potential benefit for smooth transition from short-term intravenous to long-term oral antiplatelet therapy. It has a plasma half-life of approximately 12 ...

Therefore, the researchers suggest discontinuing daprodustat to reduce the risk of recurrent ischemic strokes.

Myocardial Infarction, Cardiovascular Disease, Prevention, Challenges, Review Abdin, A. (2024) Myocardial Infarction and the Prevention Strategies Keeping it at Bay: A Narrative Review. Open Access ...

Heart health is a major concern for millions of people worldwide, and finding safer ways to prevent heart attacks and strokes ...